Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,999404,half-life,In the plasma of rabbit and cat as well as man the decline of 3H-activity was biphasic after i.v. administration with a half-life of 15 hr in the rabbit 6 hr in cat and man for the slower phase.,Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),h,15,11226,DB01064,Isoprenaline
,999404,volume of distribution,The pharmacokinetic analysis of the post-infusion data in man resulted in an open two-compartment model with a high volume of distribution (ca. 700 liters).,Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),l,700,11227,DB01064,Isoprenaline
,999404,total clearance,The total clearance (1400 ml/min) was rather high.,Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),[ml] / [min],1400,11228,DB01064,Isoprenaline
,999404,renal clearance,The renal clearance contributed to 10 per cent only.,Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),%,10,11229,DB01064,Isoprenaline
,999404,amount of drug absorbed,"The amount of drug absorbed after oral administration amounted to 44%, the reduced biovailability of 10 per cent indicated a fist-pass effect.",Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),%,44,11230,DB01064,Isoprenaline
,999404,biovailability,"The amount of drug absorbed after oral administration amounted to 44%, the reduced biovailability of 10 per cent indicated a fist-pass effect.",Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),%,10,11231,DB01064,Isoprenaline
,18218783,heart rate,Administration of fingolimod decreased heart rate from 73 +/- 11 bpm predose to a nadir of 57 +/- 8 bpm.,A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18218783/),bpm,73,11518,DB01064,Isoprenaline
,18218783,heart rate,Administration of fingolimod decreased heart rate from 73 +/- 11 bpm predose to a nadir of 57 +/- 8 bpm.,A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18218783/),bpm,57,11519,DB01064,Isoprenaline
,2884679,Plasma clearances,Plasma clearances were rapid (67-78 ml/min) and the compounds were widely distributed.,Pharmacokinetics and excretion of unique beta-adrenergic agonists. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884679/),[ml] / [min],67-78,20211,DB01064,Isoprenaline
,7624261,oral clearance,"Mean oral clearance values for S- and R-metoprolol were 1320 and 2346 ml/minute, respectively.","Lymphocyte beta 2-receptor activity, metoprolol kinetics, and response to metoprolol in hypertensive black men. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624261/),[ml] / [min],1320,20838,DB01064,Isoprenaline
,7624261,oral clearance,"Mean oral clearance values for S- and R-metoprolol were 1320 and 2346 ml/minute, respectively.","Lymphocyte beta 2-receptor activity, metoprolol kinetics, and response to metoprolol in hypertensive black men. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624261/),[ml] / [min],2346,20839,DB01064,Isoprenaline
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,15.8,21283,DB01064,Isoprenaline
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,21.8,21284,DB01064,Isoprenaline
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30.5,21285,DB01064,Isoprenaline
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30-35,21286,DB01064,Isoprenaline
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,15.8,21287,DB01064,Isoprenaline
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,21.8,21288,DB01064,Isoprenaline
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30.5,21289,DB01064,Isoprenaline
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30-35,21290,DB01064,Isoprenaline
,6116195,half-life,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,4.4,21291,DB01064,Isoprenaline
,6116195,half-life,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,5.9,21292,DB01064,Isoprenaline
,6116195,serum half-like,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,1.4,21293,DB01064,Isoprenaline
,6116195,serum half-like,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,1.3,21294,DB01064,Isoprenaline
,1378967,TmPi/GFR,In the saline-infused control group the TmPi/GFR was 2.87 +/- 0.19 mumol/ml (n = 8).,Isoproterenol infusion increases the maximal tubular capacity of phosphate reabsorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1378967/),[μM] / [ml],2.87,21971,DB01064,Isoprenaline
,1378967,TmPi/GFR,"When isoproterenol was infused intravenously at a rate of 0.005 mg/kg/min, urinary cAMP excretion was significantly increased and the TmPi/GFR was 3.53 +/- 0.17 mumol/ml (n = 10, p less than 0.05).",Isoproterenol infusion increases the maximal tubular capacity of phosphate reabsorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1378967/),[μM] / [ml],3.53,21972,DB01064,Isoprenaline
,1378967,TmPi/GFR,In the PTH-infused group (33 U/kg bolus followed by a sustaining infusion of 1 U/kg/min) TmPi/GFR was 1.69 +/- 0.15 mumol/ml (n = 9).,Isoproterenol infusion increases the maximal tubular capacity of phosphate reabsorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1378967/),[μM] / [ml],1.69,21973,DB01064,Isoprenaline
,1378967,TmPi/GFR,Coadministration of isoproterenol and PTH significantly increased the TmPi/GFR to 3.25 +/- 0.64 mumol/ml (n = 9).,Isoproterenol infusion increases the maximal tubular capacity of phosphate reabsorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1378967/),[μM] / [ml],3.25,21974,DB01064,Isoprenaline
more,26592698,gastric residence,In vitro wash off and buoyancy test in gastric media revealed that the beads containing CaCO3 has gastric residence of more than 12 h.,Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),,12,27155,DB01064,Isoprenaline
,26592698,relative oral bioavailability,"Pharmacokinetic study performed in rabbit model showed that the relative oral bioavailability of MT after administration of oral solution, sustain release and optimized formulation was 51%, 67% and 87%, respectively.",Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),%,51,27156,DB01064,Isoprenaline
,26592698,relative oral bioavailability,"Pharmacokinetic study performed in rabbit model showed that the relative oral bioavailability of MT after administration of oral solution, sustain release and optimized formulation was 51%, 67% and 87%, respectively.",Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),%,67,27157,DB01064,Isoprenaline
,26592698,relative oral bioavailability,"Pharmacokinetic study performed in rabbit model showed that the relative oral bioavailability of MT after administration of oral solution, sustain release and optimized formulation was 51%, 67% and 87%, respectively.",Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),%,87,27158,DB01064,Isoprenaline
,427002,Plasma half time,Plasma half time was 2.9 +/- 0.3 (s.e. mean) h for both routes; peak drug levels occurred 1--2 h after ingestion and bioavailability was 53%.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),h,2.9,30762,DB01064,Isoprenaline
,427002,bioavailability,Plasma half time was 2.9 +/- 0.3 (s.e. mean) h for both routes; peak drug levels occurred 1--2 h after ingestion and bioavailability was 53%.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),%,53,30763,DB01064,Isoprenaline
,427002,Plasma protein binding,Plasma protein binding was 38% and was independent of plasma concentration; the drug was not concentrated in the red cell.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),%,38,30764,DB01064,Isoprenaline
,973955,half-life,The half-life of atenolol in blood was calculated to ablut 9 hours.,"Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/973955/),h,9,33107,DB01064,Isoprenaline
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,7.5,37713,DB01064,Isoprenaline
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,10,37714,DB01064,Isoprenaline
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,5,37715,DB01064,Isoprenaline
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,86.4,37716,DB01064,Isoprenaline
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,87.8,37717,DB01064,Isoprenaline
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,83.6,37718,DB01064,Isoprenaline
,8489559,minimum concentration,"A minimum concentration of 40-60 ng/ml drug in plasma was maintained during 1-10 h, and there has been a minimum of about 40-50% of beta-blockade during 1-9 h post administration.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),[ng] / [ml],40-60,37719,DB01064,Isoprenaline
,8429110,dosing rate,"The average ISO dosing rate was 0.30 micrograms/kg/minute for the whole study population, ranging from 0.01 to 5.5 micrograms/kg/minute.",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),[μg] / [kg·min],0.30,39453,DB01064,Isoprenaline
,8429110,dosing rate,"The average ISO dosing rate was 0.30 micrograms/kg/minute for the whole study population, ranging from 0.01 to 5.5 micrograms/kg/minute.",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),[μg] / [kg·min],0.01 to 5.5,39454,DB01064,Isoprenaline
,8429110,steady-state plasma concentrations,"The POC patients received a significantly lower dosing rate than the RAD patients (0.029 +/- 0.002 vs 0.50 +/- 0.21 micrograms/kg/minute, P < .0001); the average steady-state plasma concentrations of ISO were also lower in the POC patients (1.3 +/- 0.3 versus 13.9 +/- 4.9 ng/mL, P < .0001).",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),[ng] / [ml],1.3,39455,DB01064,Isoprenaline
,8429110,steady-state plasma concentrations,"The POC patients received a significantly lower dosing rate than the RAD patients (0.029 +/- 0.002 vs 0.50 +/- 0.21 micrograms/kg/minute, P < .0001); the average steady-state plasma concentrations of ISO were also lower in the POC patients (1.3 +/- 0.3 versus 13.9 +/- 4.9 ng/mL, P < .0001).",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),[ng] / [ml],13.9,39456,DB01064,Isoprenaline
,8429110,steady-state plasma concentration,"The steady-state plasma concentration, normalized to a dosing rate of .05 micrograms/kg/minute, was 1.9 +/- 0.3 ng/mL for all patients, and the clearance was 42.5 +/- 5.0 mg/kg/minute.",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),[ng] / [ml],1.9,39457,DB01064,Isoprenaline
,8429110,clearance,"The steady-state plasma concentration, normalized to a dosing rate of .05 micrograms/kg/minute, was 1.9 +/- 0.3 ng/mL for all patients, and the clearance was 42.5 +/- 5.0 mg/kg/minute.",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),[mg] / [kg·min],42.5,39458,DB01064,Isoprenaline
,8429110,normalized steady-state plasma concentration,"Postoperative cardiac patients had a significant higher normalized steady-state plasma concentration and moderately significant lower clearance than did RAD patients (2.1 +/- 0.3 versus 1.7 +/- 0.4 ng/mL, P < .05 and 33.2 +/- 4.9 versus 48.4 +/- 7.3, P < .06, respectively).",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),[ng] / [ml],2.1,39459,DB01064,Isoprenaline
,8429110,clearance,"Postoperative cardiac patients had a significant higher normalized steady-state plasma concentration and moderately significant lower clearance than did RAD patients (2.1 +/- 0.3 versus 1.7 +/- 0.4 ng/mL, P < .05 and 33.2 +/- 4.9 versus 48.4 +/- 7.3, P < .06, respectively).",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),[ng] / [ml],1.7,39460,DB01064,Isoprenaline
,8429110,clearance,"Postoperative cardiac patients had a significant higher normalized steady-state plasma concentration and moderately significant lower clearance than did RAD patients (2.1 +/- 0.3 versus 1.7 +/- 0.4 ng/mL, P < .05 and 33.2 +/- 4.9 versus 48.4 +/- 7.3, P < .06, respectively).",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),,33.2,39461,DB01064,Isoprenaline
,8429110,clearance,"Postoperative cardiac patients had a significant higher normalized steady-state plasma concentration and moderately significant lower clearance than did RAD patients (2.1 +/- 0.3 versus 1.7 +/- 0.4 ng/mL, P < .05 and 33.2 +/- 4.9 versus 48.4 +/- 7.3, P < .06, respectively).",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),,48.4,39462,DB01064,Isoprenaline
,8429110,plasma half-life,"The average plasma half-life of ISO was 4.2 +/- 1.5 minutes, and the volume of distribution was 216 +/- 57 mg/kg.",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),min,4.2,39463,DB01064,Isoprenaline
,8429110,volume of distribution,"The average plasma half-life of ISO was 4.2 +/- 1.5 minutes, and the volume of distribution was 216 +/- 57 mg/kg.",The pharmacokinetics of isoproterenol in critically ill pediatric patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429110/),[mg] / [kg],216,39464,DB01064,Isoprenaline
,2883988,plasma elimination half-life,The plasma elimination half-life was 47.6 +/- 8.1 h.,"The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2883988/),h,47.6,42931,DB01064,Isoprenaline
less,8811433,half-life of elimination,Isoproterenol is a chiral catecholamine with a half-life of elimination of less than 10 min.,Optimization of the separation and detection of the enantiomers of isoproterenol in microdialysis samples by cyclodextrin-modified capillary electrophoresis using electrochemical detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8811433/),min,10,47618,DB01064,Isoprenaline
,8811433,detection limits,The detection limits were decreased three orders of magnitude to 3 ng/ml by using an amperometric detector.,Optimization of the separation and detection of the enantiomers of isoproterenol in microdialysis samples by cyclodextrin-modified capillary electrophoresis using electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8811433/),[ng] / [ml],3,47619,DB01064,Isoprenaline
,8811433,detection limits,The detection limits were decreased to 0.6 ng/ml using an on-column concentration technique in which peak stacking was accomplished by following the sample injection with a plug of acid.,Optimization of the separation and detection of the enantiomers of isoproterenol in microdialysis samples by cyclodextrin-modified capillary electrophoresis using electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8811433/),[ng] / [ml],0.6,47620,DB01064,Isoprenaline
,8103764,half-life for the elimination phase,Timolol was eliminated from plasma with a mean half-life for the elimination phase of 2.6 hours.,The analysis of plasma kinetics and beta-receptor binding and -blocking activity of timolol following its small intravenous dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103764/),h,2.6,51856,DB01064,Isoprenaline
,548592,blood flow,Glucagon given i.v. at 10 microgram/min caused blood flow to rise by 81% and inulin clearance to rise by 25% from 1.88 +/- 0.16 to 2.35 +/- 0.19 ml/min (P less than 0.05).,Peritoneal clearance of creatinine and inulin during dialysis in dogs: effect of splanchnic vasodilators. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/548592/),[ml] / [min],1.88,56604,DB01064,Isoprenaline
,8866453,terminal elimination half-life (t1/2),"The terminal elimination half-life (t1/2) for 4'-OHP was 69.4 min, the apparent volume of distribution (Vd) was 3.39 L/kg and the total clearance (Clt) was 53.6 mL/min.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),min,69.4,59495,DB01064,Isoprenaline
,8866453,apparent volume of distribution (Vd),"The terminal elimination half-life (t1/2) for 4'-OHP was 69.4 min, the apparent volume of distribution (Vd) was 3.39 L/kg and the total clearance (Clt) was 53.6 mL/min.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[l] / [kg],3.39,59496,DB01064,Isoprenaline
,8866453,total clearance (Clt),"The terminal elimination half-life (t1/2) for 4'-OHP was 69.4 min, the apparent volume of distribution (Vd) was 3.39 L/kg and the total clearance (Clt) was 53.6 mL/min.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ml] / [min],53.6,59497,DB01064,Isoprenaline
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],30,59498,DB01064,Isoprenaline
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],60,59499,DB01064,Isoprenaline
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],120,59500,DB01064,Isoprenaline
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],240,59501,DB01064,Isoprenaline
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],480,59502,DB01064,Isoprenaline
,29958697,terminal half-life,"A small single i.v. dose of [125I]TLQP-21 had a terminal half-life of 110 min with a terminal clearance rate constant, kt, of 0.0063/min, and an initial half-life of 0.97 min with an initial clearance rate constant, ki, of 0.71/min.",Clearance kinetics of the VGF-derived neuropeptide TLQP-21. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29958697/),min,110,69562,DB01064,Isoprenaline
,29958697,"terminal clearance rate constant, kt,","A small single i.v. dose of [125I]TLQP-21 had a terminal half-life of 110 min with a terminal clearance rate constant, kt, of 0.0063/min, and an initial half-life of 0.97 min with an initial clearance rate constant, ki, of 0.71/min.",Clearance kinetics of the VGF-derived neuropeptide TLQP-21. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29958697/),1/[min],0.0063,69563,DB01064,Isoprenaline
,29958697,initial half-life,"A small single i.v. dose of [125I]TLQP-21 had a terminal half-life of 110 min with a terminal clearance rate constant, kt, of 0.0063/min, and an initial half-life of 0.97 min with an initial clearance rate constant, ki, of 0.71/min.",Clearance kinetics of the VGF-derived neuropeptide TLQP-21. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29958697/),min,0.97,69564,DB01064,Isoprenaline
,29958697,"initial clearance rate constant, ki","A small single i.v. dose of [125I]TLQP-21 had a terminal half-life of 110 min with a terminal clearance rate constant, kt, of 0.0063/min, and an initial half-life of 0.97 min with an initial clearance rate constant, ki, of 0.71/min.",Clearance kinetics of the VGF-derived neuropeptide TLQP-21. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29958697/),1/[min],0.71,69565,DB01064,Isoprenaline
,2454374,half-life,Calculation of the half-life of carvedilol gave values of 2.2 to 9 h.,Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454374/),h,2.2 to 9,83799,DB01064,Isoprenaline
,2454374,volume of distribution,The volume of distribution was found to be 1.54 l/kg and the total body clearance was 0.521 l/h/kg.,Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454374/),[l] / [kg],1.54,83800,DB01064,Isoprenaline
,2454374,total body clearance,The volume of distribution was found to be 1.54 l/kg and the total body clearance was 0.521 l/h/kg.,Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454374/),[l] / [h·kg],0.521,83801,DB01064,Isoprenaline
,23136717,binding constant (Kb),"In CZE, the binding constant (Kb) was 4.07 x 10(4) M(-1) (298 K) and 4.76 x 10(4) M(-1) (310K) using the Scatchard analysis.",Interactions between isoprenaline hydrochloride and bovine serum albumin (BSA) in capillary zone electrophoresis and affinity capillary electrophoresis. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136717/),1/[M],4.07 x 10(4),84601,DB01064,Isoprenaline
,23136717,binding constant (Kb),"In CZE, the binding constant (Kb) was 4.07 x 10(4) M(-1) (298 K) and 4.76 x 10(4) M(-1) (310K) using the Scatchard analysis.",Interactions between isoprenaline hydrochloride and bovine serum albumin (BSA) in capillary zone electrophoresis and affinity capillary electrophoresis. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136717/),1/[M],4.76 x 10(4),84602,DB01064,Isoprenaline
,23136717,deltaG,"At 298 K, deltaG, deltaH, and deltaS were -26.30 kJ x mol(-1), 10.02 kJ x mol(-1), and 0.12 kJ x mol(-) x K(-1), respectively.",Interactions between isoprenaline hydrochloride and bovine serum albumin (BSA) in capillary zone electrophoresis and affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136717/),[kj] / [mol],-,84603,DB01064,Isoprenaline
,23136717,deltaG,"At 298 K, deltaG, deltaH, and deltaS were -26.30 kJ x mol(-1), 10.02 kJ x mol(-1), and 0.12 kJ x mol(-) x K(-1), respectively.",Interactions between isoprenaline hydrochloride and bovine serum albumin (BSA) in capillary zone electrophoresis and affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136717/),[kj] / [mol],26.30,84604,DB01064,Isoprenaline
,23136717,deltaH,"At 298 K, deltaG, deltaH, and deltaS were -26.30 kJ x mol(-1), 10.02 kJ x mol(-1), and 0.12 kJ x mol(-) x K(-1), respectively.",Interactions between isoprenaline hydrochloride and bovine serum albumin (BSA) in capillary zone electrophoresis and affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136717/),[kj] / [mol],26.30,84605,DB01064,Isoprenaline
,23136717,deltaH,"At 298 K, deltaG, deltaH, and deltaS were -26.30 kJ x mol(-1), 10.02 kJ x mol(-1), and 0.12 kJ x mol(-) x K(-1), respectively.",Interactions between isoprenaline hydrochloride and bovine serum albumin (BSA) in capillary zone electrophoresis and affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136717/),[kj] / [mol],10.02,84606,DB01064,Isoprenaline
,23136717,deltaS,"At 298 K, deltaG, deltaH, and deltaS were -26.30 kJ x mol(-1), 10.02 kJ x mol(-1), and 0.12 kJ x mol(-) x K(-1), respectively.",Interactions between isoprenaline hydrochloride and bovine serum albumin (BSA) in capillary zone electrophoresis and affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136717/),[kj·mol(-] / [k],0.12,84607,DB01064,Isoprenaline
,23136717,deltaG,"The deltaG at 310K was -27.76 kJ x mol(-1), whereas the deltaH and deltaS at 310 K were identical with that at 298 K.",Interactions between isoprenaline hydrochloride and bovine serum albumin (BSA) in capillary zone electrophoresis and affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136717/),[kj] / [mol],-27.76,84608,DB01064,Isoprenaline
,23136717,mobility ratio (,"In ACE, a more reliable parameter, mobility ratio (M), was applied in the calculation of Kb. Kb (310K) obtained through this method was 9.80 x 10(4) and 9.24 x 10(4) M(-1) when IH and BSA were added to the buffer in varying concentrations, respectively.",Interactions between isoprenaline hydrochloride and bovine serum albumin (BSA) in capillary zone electrophoresis and affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136717/),1/[M],9.80 x 10(4),84609,DB01064,Isoprenaline
,23136717,Kb,"In ACE, a more reliable parameter, mobility ratio (M), was applied in the calculation of Kb. Kb (310K) obtained through this method was 9.80 x 10(4) and 9.24 x 10(4) M(-1) when IH and BSA were added to the buffer in varying concentrations, respectively.",Interactions between isoprenaline hydrochloride and bovine serum albumin (BSA) in capillary zone electrophoresis and affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136717/),1/[M],9.80 x 10(4),84610,DB01064,Isoprenaline
,23136717,Kb,"In ACE, a more reliable parameter, mobility ratio (M), was applied in the calculation of Kb. Kb (310K) obtained through this method was 9.80 x 10(4) and 9.24 x 10(4) M(-1) when IH and BSA were added to the buffer in varying concentrations, respectively.",Interactions between isoprenaline hydrochloride and bovine serum albumin (BSA) in capillary zone electrophoresis and affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136717/),1/[M],9.24 x 10(4),84611,DB01064,Isoprenaline
,14709906,detection limit,The detection limit of sotalol by the enzyme-linked immunosorbent assay was approximately 32 ng/ml with 50-microl samples.,Establishment of an enzyme-linked immunosorbent assay for measurement of sotalol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14709906/),[ng] / [ml],32,85188,DB01064,Isoprenaline
,9292,steady-state alprenolol concentration,"Although there was interindividual variability in the mean steady-state alprenolol concentration (range 11 - 141 ng/ml), and in the degree of beta-blockade (7-fold), the correlation between the two variables was highly significant (r = 0.80, p less than 0.001).",Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. I. Relationship between plasma concentration and adrenergic beta-receptor blockade. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9292/),[ng] / [ml],11 - 141,87619,DB01064,Isoprenaline
,17072092,systemic clearances,"Increased blood bisoprolol concentrations accompanied decreased mean systemic clearances: 50.7, 36.4, and 26.2 mL/min/kg in control, RAO, and BUL rats, respectively.",Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17072092/),[ml] / [kg·min],50.7,96241,DB01064,Isoprenaline
,17072092,systemic clearances,"Increased blood bisoprolol concentrations accompanied decreased mean systemic clearances: 50.7, 36.4, and 26.2 mL/min/kg in control, RAO, and BUL rats, respectively.",Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17072092/),[ml] / [kg·min],36.4,96242,DB01064,Isoprenaline
,17072092,systemic clearances,"Increased blood bisoprolol concentrations accompanied decreased mean systemic clearances: 50.7, 36.4, and 26.2 mL/min/kg in control, RAO, and BUL rats, respectively.",Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17072092/),[ml] / [kg·min],26.2,96243,DB01064,Isoprenaline
,2389694,"area under the heart rate response, time curve","The area under the heart rate response, time curve after nadolol withdrawal was significantly less than that after propranolol withdrawal (20.3 beats/min.",Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389694/),[beats] / [min],20.3,117231,DB01064,Isoprenaline
,3855472,half-life (t 1/2),[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),min,30,126941,DB01064,Isoprenaline
,3855472,terminal phase (t 1/2,[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),h,17,126942,DB01064,Isoprenaline
,501565,t 1/2,The t 1/2 of this drug (4.30 +/- 0.40 hr) in dogs was longer than that of other beta adrenergic blockers.,Relationship between pharmacokinetics and pharmacodynamics of the beta adrenergic blocking drug sotalol in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/501565/),h,4.30,131631,DB01064,Isoprenaline
,501565,renal clearance of the drug,The renal clearance of the drug (4.21 +/- 0.31 ml/min/kg) was approximately 90% of total plasma clearance together with an extensive fraction excreted unchanged (72 +/- 12% of dose) in urine.,Relationship between pharmacokinetics and pharmacodynamics of the beta adrenergic blocking drug sotalol in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/501565/),[ml] / [kg·min],4.21,131632,DB01064,Isoprenaline
,10190880,Baroreflex sensitivity,"Baroreflex sensitivity was lower in patients (12+/-1 versus 18+/-2 ms/mm Hg, P<0.02), but the intrinsic heart rate was similar in both groups.",Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190880/),[ms] / [hg·mm],12,134898,DB01064,Isoprenaline
,10190880,Baroreflex sensitivity,"Baroreflex sensitivity was lower in patients (12+/-1 versus 18+/-2 ms/mm Hg, P<0.02), but the intrinsic heart rate was similar in both groups.",Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190880/),[ms] / [hg·mm],18,134899,DB01064,Isoprenaline
,3701908,total dose,An estimated total dose of 1.2 gm.,Intravenous lidocaine overdosage in a child. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701908/),gm,1.2,154160,DB01064,Isoprenaline
,2539818,unbound [3H,"AAG-treated rats had greater [3H]propranolol binding in serum (93.0 +/- 3.2 vs 76.7 +/- 3.0%, P less than 0.01) and a lower calculated unbound [3H]propranolol concentration in serum (2.7 +/- 1.3 vs 7.4 +/- 3.1 X 10(6) dpm/ml, P less than 0.001) than albumin-treated rats.",Effects of alpha-1-acid glycoprotein administration on propranolol binding and beta blockade in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2539818/),[dpm] / [ml],2.7,162881,DB01064,Isoprenaline
,2539818,unbound [3H,"AAG-treated rats had greater [3H]propranolol binding in serum (93.0 +/- 3.2 vs 76.7 +/- 3.0%, P less than 0.01) and a lower calculated unbound [3H]propranolol concentration in serum (2.7 +/- 1.3 vs 7.4 +/- 3.1 X 10(6) dpm/ml, P less than 0.001) than albumin-treated rats.",Effects of alpha-1-acid glycoprotein administration on propranolol binding and beta blockade in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2539818/),[dpm] / [ml],7.4,162882,DB01064,Isoprenaline
,8807020,apparent volume of distribution at steady state,"After i.v. administration, mean +/- SD apparent volume of distribution at steady state and systemic clearance values were 1,088 +/- 148 ml/kg and 259 +/- 72 ml/h/kg, respectively.",Pharmacokinetics of atenolol in clinically normal cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807020/),[ml] / [kg],"1,088",166372,DB01064,Isoprenaline
,8807020,systemic clearance,"After i.v. administration, mean +/- SD apparent volume of distribution at steady state and systemic clearance values were 1,088 +/- 148 ml/kg and 259 +/- 72 ml/h/kg, respectively.",Pharmacokinetics of atenolol in clinically normal cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807020/),[ml] / [h·kg],259,166373,DB01064,Isoprenaline
,8807020,Bioavailability,Bioavailability was 90 +/- 9% after oral administration.,Pharmacokinetics of atenolol in clinically normal cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807020/),%,90,166374,DB01064,Isoprenaline
,8807020,half-life,"The half-life values were 3.44 +/- 0.5 and 3.66 +/- 0.39 hours after i.v. and oral administrations, respectively.",Pharmacokinetics of atenolol in clinically normal cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807020/),h,3.44,166375,DB01064,Isoprenaline
,8807020,half-life,"The half-life values were 3.44 +/- 0.5 and 3.66 +/- 0.39 hours after i.v. and oral administrations, respectively.",Pharmacokinetics of atenolol in clinically normal cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807020/),h,3.66,166376,DB01064,Isoprenaline
,20020526,concentrations,"AGP concentrations at 2 and 7 days postsurgery were 708 +/- 274 and 176 +/- 111 microg/mL (mean +/- SE), respectively.","Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020526/),[μg] / [ml],708,167748,DB01064,Isoprenaline
,20020526,concentrations,"AGP concentrations at 2 and 7 days postsurgery were 708 +/- 274 and 176 +/- 111 microg/mL (mean +/- SE), respectively.","Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020526/),[μg] / [ml],176,167749,DB01064,Isoprenaline
,20020526,K(B,"Individual values of AGP concentrations ranged between 110 and 1150 microg/mL, and were associated with K(B,vivo) values of S(-)-propranolol from 7.0 to 30 nM.","Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)). ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020526/),nM,7.0 to 30,167750,DB01064,Isoprenaline
,8433408,apparent plasma half-life,Plasma levels of astemizole plus hydroxylated metabolites showed an apparent plasma half-life of 17 h.,Prolonged QT interval and torsade de pointes following astemizole overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8433408/),h,17,168585,DB01064,Isoprenaline
,6616139,half-life,The clearance of 14C-misonidazole from the tumours and all normal tissues could be characterised by two distinct phases: a rapid phase (0.7 h half-life) followed by a much slower phase (approximately 50 h half-life).,The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6616139/),h,0.7,180118,DB01064,Isoprenaline
,6616139,half-life,The clearance of 14C-misonidazole from the tumours and all normal tissues could be characterised by two distinct phases: a rapid phase (0.7 h half-life) followed by a much slower phase (approximately 50 h half-life).,The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6616139/),h,50,180119,DB01064,Isoprenaline
,8331202,biologic half-life,"As the serum creatinine concentration returned slowly to baseline with good diuresis, the concentration of atenolol decreased (biologic half-life = 2.95 days) and the blood pressure gradually recovered.",Impaired elimination of atenolol in a nephropathic patient with self-medication overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331202/),d,2.95,184252,DB01064,Isoprenaline
,12350290,pA(2),"HCl 6 is a highly specific beta(1)-adrenoceptor antagonist (pA(2) = 8.15+/-0.22, beta(1)/beta(2) selectivity > 4400).","Synthesis, beta-adrenoceptor pharmacology and toxicology of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting beta(1)-specific antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12350290/),,8.15,189193,DB01064,Isoprenaline
>,12350290,beta(1)/beta(2) selectivity,"HCl 6 is a highly specific beta(1)-adrenoceptor antagonist (pA(2) = 8.15+/-0.22, beta(1)/beta(2) selectivity > 4400).","Synthesis, beta-adrenoceptor pharmacology and toxicology of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting beta(1)-specific antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12350290/),,4400,189194,DB01064,Isoprenaline
<,12350290,half-life,HCl 6 and esmolol have very short durations of action after intravenous infusion in the rat (pharmacodynamic half-life is < 15 min for D140S.HCl and 10 min for esmolol).,"Synthesis, beta-adrenoceptor pharmacology and toxicology of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting beta(1)-specific antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12350290/),min,15,189195,DB01064,Isoprenaline
,12350290,half-life,HCl 6 and esmolol have very short durations of action after intravenous infusion in the rat (pharmacodynamic half-life is < 15 min for D140S.HCl and 10 min for esmolol).,"Synthesis, beta-adrenoceptor pharmacology and toxicology of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting beta(1)-specific antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12350290/),min,10,189196,DB01064,Isoprenaline
,7678675,pulmonary extractions,"Statistically significant pulmonary extractions were observed for NA (8.8%) and DA (24.0%), but not for A and ISO.",Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,8.8,190327,DB01064,Isoprenaline
,7678675,pulmonary extractions,"Statistically significant pulmonary extractions were observed for NA (8.8%) and DA (24.0%), but not for A and ISO.",Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,24.0,190328,DB01064,Isoprenaline
,7678675,systemic extraction,The systemic extraction was lowest for ISO (63%) and highest for DA (75%).,Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,63,190329,DB01064,Isoprenaline
,7678675,systemic extraction,The systemic extraction was lowest for ISO (63%) and highest for DA (75%).,Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,75,190330,DB01064,Isoprenaline
,10800722,Specific activities,Specific activities ranged from 26.5-39.3 TBq (about 700-1000 Ci)/mmol and the radiochemical yield was 2.4-8.6% (corrected for decay).,"Synthesis and biodistribution of [11c]procaterol, a beta2-adrenoceptor agonist for positron emission tomography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800722/),tbq,26.5-39.3,199523,DB01064,Isoprenaline
,10800722,t1/2,"The clearance of [11C]procaterol was biphasic, with a rapid distribution phase (t1/2 0.17 min) representing 90% of the injected dose followed by an elimination phase (t1/2 18.1 min).","Synthesis and biodistribution of [11c]procaterol, a beta2-adrenoceptor agonist for positron emission tomography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800722/),min,0.17,199524,DB01064,Isoprenaline
,10800722,t1/2,"The clearance of [11C]procaterol was biphasic, with a rapid distribution phase (t1/2 0.17 min) representing 90% of the injected dose followed by an elimination phase (t1/2 18.1 min).","Synthesis and biodistribution of [11c]procaterol, a beta2-adrenoceptor agonist for positron emission tomography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800722/),min,18.1,199525,DB01064,Isoprenaline
,10800722,total/non-specific binding ratios,"In a dynamic PET-study, the lungs of untreated control rats could barely be detected and total/non-specific binding ratios rose to only 1.2 at 20 min postinjection.","Synthesis and biodistribution of [11c]procaterol, a beta2-adrenoceptor agonist for positron emission tomography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800722/),,1.2,199526,DB01064,Isoprenaline
,2890664,steady-state concentration,The mean +/- standard deviation steady-state concentration of flestolol was 31.1 +/- 12.0 ng/mL.,"Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890664/),[ng] / [ml],31.1,201851,DB01064,Isoprenaline
,2890664,elimination half-life,The elimination half-life averaged 7.2 minutes.,"Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890664/),min,7.2,201852,DB01064,Isoprenaline
,2890664,total body clearance,The mean +/- standard deviation total body clearance was 181 +/- 66 mL/min/kg.,"Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890664/),[ml] / [kg·min],181,201853,DB01064,Isoprenaline
,2890664,apparent volume of distribution,"The apparent volume of distribution and the area under the curve averaged 1.89 L/kg and 2.23 micrograms-hr/mL, respectively.","Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890664/),[l] / [kg],1.89,201854,DB01064,Isoprenaline
,2890664,area under the curve,"The apparent volume of distribution and the area under the curve averaged 1.89 L/kg and 2.23 micrograms-hr/mL, respectively.","Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890664/),[μgrams-hr] / [ml],2.23,201855,DB01064,Isoprenaline
,9449399,metabolic clearance rate,"Insulin secretion (ie, C-peptide concentrations) was not affected by any of the treatments; however, phenylephrine significantly reduced the metabolic clearance rate of insulin (MCRinsulin) (16.6+/-1.0 mL/kg per minute with placebo versus 13.6+/-0.7 mL/kg per minute with phenylephrine, P<.01) and thereby increased plasma insulin concentrations (66+/-5.1 microU/mL with placebo versus 79+/-4.1 microU/mL with phenylephrine, P<.05).",Acute effects of blood pressure elevation on insulin clearance in normotensive healthy subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449399/),[ml] / [kg·min],16.6,209898,DB01064,Isoprenaline
,9449399,metabolic clearance rate,"Insulin secretion (ie, C-peptide concentrations) was not affected by any of the treatments; however, phenylephrine significantly reduced the metabolic clearance rate of insulin (MCRinsulin) (16.6+/-1.0 mL/kg per minute with placebo versus 13.6+/-0.7 mL/kg per minute with phenylephrine, P<.01) and thereby increased plasma insulin concentrations (66+/-5.1 microU/mL with placebo versus 79+/-4.1 microU/mL with phenylephrine, P<.05).",Acute effects of blood pressure elevation on insulin clearance in normotensive healthy subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449399/),[ml] / [kg·min],13.6,209899,DB01064,Isoprenaline
,9449399,glucose utilization,"Phenylephrine also increased glucose utilization (42+/-5.8 micromol/kg per minute during placebo versus 58+/-4.8 micromol/kg per minute during phenylephrine, P<.05); however, this was proportional to the increased insulin concentrations; therefore, insulin sensitivity was unchanged.",Acute effects of blood pressure elevation on insulin clearance in normotensive healthy subjects. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449399/),[μM] / [kg·min],42,209900,DB01064,Isoprenaline
,9449399,glucose utilization,"Phenylephrine also increased glucose utilization (42+/-5.8 micromol/kg per minute during placebo versus 58+/-4.8 micromol/kg per minute during phenylephrine, P<.05); however, this was proportional to the increased insulin concentrations; therefore, insulin sensitivity was unchanged.",Acute effects of blood pressure elevation on insulin clearance in normotensive healthy subjects. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449399/),[μM] / [kg·min],58,209901,DB01064,Isoprenaline
,9449399,glucose utilization,"MCRinsulin and plasma insulin concentrations were not affected by angiotensin II; however, glucose utilization increased to 51+/-2.7 micromol/kg per minute (P<.01 versus placebo), indicating insulin sensitivity was increased.",Acute effects of blood pressure elevation on insulin clearance in normotensive healthy subjects. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449399/),[μM] / [kg·min],51,209902,DB01064,Isoprenaline
,2439812,elimination half-life,"In pharmacokinetic terms, however, these drugs show no pronounced difference in their elimination half-life (ranging between 4 and 8 h).",Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439812/),h,4 and 8,210689,DB01064,Isoprenaline
,32532591,total distribution volumes,Its brain pharmacokinetics showed that the concentration of isoproterenol in the brain at equilibrium was about two-fold higher than in the plasma (total distribution volumes 2.0 ± 0.2 cm3/mL).,Brain pharmacokinetics and biodistribution of 11C-labeled isoproterenol in rodents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32532591/),[cm3] / [ml],2.0,215665,DB01064,Isoprenaline
,489770,biological half-life,The processes of distribution and elimination are of first order; the intravenous biological half-life is 6 to 8 hours.,Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/489770/),h,6 to 8,222857,DB01064,Isoprenaline
,28884552,AUC0-∞,"In the comparison of main pharmacokinetic parameters between two groups: AUC0-∞=(11.451±3.228) mg•h•L⁻¹,AUC0-t=(14.047±3.765) mg•h•L⁻¹, Cmax=(5.623±1.40) mg•L⁻¹ in normal group; AUC0-∞=(68.849±50.396 9) mg•h•L⁻¹, AUC0-t= (58.312±45.802) mg•h•L⁻¹,Cmax=(18.456±7.517) mg•L⁻¹ in treatment group.",[Effect of puerarin in Longmaining formula on pharmacokinetics-pharmacodynamics correlation in rats with myocardial ischemia]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28884552/),h·l⁻¹·mg,11.451,240348,DB01064,Isoprenaline
,28884552,AUC0-t,"In the comparison of main pharmacokinetic parameters between two groups: AUC0-∞=(11.451±3.228) mg•h•L⁻¹,AUC0-t=(14.047±3.765) mg•h•L⁻¹, Cmax=(5.623±1.40) mg•L⁻¹ in normal group; AUC0-∞=(68.849±50.396 9) mg•h•L⁻¹, AUC0-t= (58.312±45.802) mg•h•L⁻¹,Cmax=(18.456±7.517) mg•L⁻¹ in treatment group.",[Effect of puerarin in Longmaining formula on pharmacokinetics-pharmacodynamics correlation in rats with myocardial ischemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28884552/),h·l⁻¹·mg,14.047,240349,DB01064,Isoprenaline
,28884552,Cmax,"In the comparison of main pharmacokinetic parameters between two groups: AUC0-∞=(11.451±3.228) mg•h•L⁻¹,AUC0-t=(14.047±3.765) mg•h•L⁻¹, Cmax=(5.623±1.40) mg•L⁻¹ in normal group; AUC0-∞=(68.849±50.396 9) mg•h•L⁻¹, AUC0-t= (58.312±45.802) mg•h•L⁻¹,Cmax=(18.456±7.517) mg•L⁻¹ in treatment group.",[Effect of puerarin in Longmaining formula on pharmacokinetics-pharmacodynamics correlation in rats with myocardial ischemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28884552/),l⁻¹·mg,5.623,240350,DB01064,Isoprenaline
,28884552,AUC0-∞,"In the comparison of main pharmacokinetic parameters between two groups: AUC0-∞=(11.451±3.228) mg•h•L⁻¹,AUC0-t=(14.047±3.765) mg•h•L⁻¹, Cmax=(5.623±1.40) mg•L⁻¹ in normal group; AUC0-∞=(68.849±50.396 9) mg•h•L⁻¹, AUC0-t= (58.312±45.802) mg•h•L⁻¹,Cmax=(18.456±7.517) mg•L⁻¹ in treatment group.",[Effect of puerarin in Longmaining formula on pharmacokinetics-pharmacodynamics correlation in rats with myocardial ischemia]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28884552/),h·l⁻¹·mg,68.849,240351,DB01064,Isoprenaline
,28884552,AUC0-t,"In the comparison of main pharmacokinetic parameters between two groups: AUC0-∞=(11.451±3.228) mg•h•L⁻¹,AUC0-t=(14.047±3.765) mg•h•L⁻¹, Cmax=(5.623±1.40) mg•L⁻¹ in normal group; AUC0-∞=(68.849±50.396 9) mg•h•L⁻¹, AUC0-t= (58.312±45.802) mg•h•L⁻¹,Cmax=(18.456±7.517) mg•L⁻¹ in treatment group.",[Effect of puerarin in Longmaining formula on pharmacokinetics-pharmacodynamics correlation in rats with myocardial ischemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28884552/),h·l⁻¹·mg,58.312,240352,DB01064,Isoprenaline
,28884552,Cmax,"In the comparison of main pharmacokinetic parameters between two groups: AUC0-∞=(11.451±3.228) mg•h•L⁻¹,AUC0-t=(14.047±3.765) mg•h•L⁻¹, Cmax=(5.623±1.40) mg•L⁻¹ in normal group; AUC0-∞=(68.849±50.396 9) mg•h•L⁻¹, AUC0-t= (58.312±45.802) mg•h•L⁻¹,Cmax=(18.456±7.517) mg•L⁻¹ in treatment group.",[Effect of puerarin in Longmaining formula on pharmacokinetics-pharmacodynamics correlation in rats with myocardial ischemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28884552/),l⁻¹·mg,18.456,240353,DB01064,Isoprenaline
,2702795,Emax,"The predicted Emax for the black group was 52.7 +/- 8.7 beats/min at a metoprolol concentration of 29.8 +/- 6.1 ng/ml, which was higher (p less than 0.05) than that in the white group, i.e., 43.7 +/- 7.3 beats/min at a concentration of 27.6 +/- 9.1 ng/ml.",Racial differences in drug response: isoproterenol effects on heart rate following intravenous metoprolol. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702795/),[beats] / [min],52.7,249620,DB01064,Isoprenaline
,2702795,Emax,"The predicted Emax for the black group was 52.7 +/- 8.7 beats/min at a metoprolol concentration of 29.8 +/- 6.1 ng/ml, which was higher (p less than 0.05) than that in the white group, i.e., 43.7 +/- 7.3 beats/min at a concentration of 27.6 +/- 9.1 ng/ml.",Racial differences in drug response: isoproterenol effects on heart rate following intravenous metoprolol. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702795/),[beats] / [min],43.7,249621,DB01064,Isoprenaline
,1636772,clearance,"The NE clearance was lower in CHF than in the control group (CHF 1.25 +/- 0.13, controls 2.04 +/- 0.22 l.min-1.m-2; P = 0.009).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],1.25,250331,DB01064,Isoprenaline
,1636772,clearance,"The NE clearance was lower in CHF than in the control group (CHF 1.25 +/- 0.13, controls 2.04 +/- 0.22 l.min-1.m-2; P = 0.009).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],2.04,250332,DB01064,Isoprenaline
,1636772,clearance,"The ISO clearance was reduced similarly in CHF (CHF 0.90 +/- 0.09, controls 1.59 +/- 0.12 l.min-1.m-2; P less than 0.001).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],0.90,250333,DB01064,Isoprenaline
,1636772,clearance,"The ISO clearance was reduced similarly in CHF (CHF 0.90 +/- 0.09, controls 1.59 +/- 0.12 l.min-1.m-2; P less than 0.001).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],1.59,250334,DB01064,Isoprenaline
,2550167,t1/2,"In a single-blind randomized study, 10 healthy men took a placebo for 1 week and then took nadolol one time a day (t1/2, 18 to 24 hours) or propranolol three times a day (t1/2, 4 to 6 hours) in doses that were increased weekly for 4 weeks to reach 240 mg per day.",Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550167/),h,18 to 24,253025,DB01064,Isoprenaline
,2550167,t1/2,"In a single-blind randomized study, 10 healthy men took a placebo for 1 week and then took nadolol one time a day (t1/2, 18 to 24 hours) or propranolol three times a day (t1/2, 4 to 6 hours) in doses that were increased weekly for 4 weeks to reach 240 mg per day.",Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550167/),h,4 to 6,253026,DB01064,Isoprenaline
,768905,late biological half-life,"It was shown, by calculation from the renal clearance, that the late biological half-life for the decline of 14C-acebutolol in plasma was 9.4 h and 13.2 h, respectively, in two of these patients treated with a single oral dose (200 mg) of 14C-acebutolol hydrochloride.",[Pharmacokinetics of acebutolol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),h,9.4,257759,DB01064,Isoprenaline
,768905,late biological half-life,"It was shown, by calculation from the renal clearance, that the late biological half-life for the decline of 14C-acebutolol in plasma was 9.4 h and 13.2 h, respectively, in two of these patients treated with a single oral dose (200 mg) of 14C-acebutolol hydrochloride.",[Pharmacokinetics of acebutolol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),h,13.2,257760,DB01064,Isoprenaline
,768905,late biological half-life plasma,"In one of the patients treated by intravenous infusion (20 mg/10 mn), the late biological half-life plasma was calculated to be 7.5 h.",[Pharmacokinetics of acebutolol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),h,7.5,257761,DB01064,Isoprenaline
,768905,Renal clearance,Renal clearance of acebutolol was shown to be close to a mean of 83 ml plasma/mn for each of three patients (two oral and one intravenous) in spite of the fact that one of the orally treated patients had an elevated level of urea in his plasma (47 mg/100 ml) indicative of some impairment of kidney function.,[Pharmacokinetics of acebutolol]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),[ml·plasma] / [mn],83,257762,DB01064,Isoprenaline
,768905,recovery of 14C,The recovery of 14C-radioactivity in the urine (29 p. cent) and faeces (64 p. cent) was 93 p.cent of the dose of labelled acebutolol in one of the orally treated patients.,[Pharmacokinetics of acebutolol]. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),cent·p,29,257763,DB01064,Isoprenaline
,768905,recovery of 14C,The recovery of 14C-radioactivity in the urine (29 p. cent) and faeces (64 p. cent) was 93 p.cent of the dose of labelled acebutolol in one of the orally treated patients.,[Pharmacokinetics of acebutolol]. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),cent·p,64,257764,DB01064,Isoprenaline
,768905,recovery of 14C,The recovery of 14C-radioactivity in the urine (29 p. cent) and faeces (64 p. cent) was 93 p.cent of the dose of labelled acebutolol in one of the orally treated patients.,[Pharmacokinetics of acebutolol]. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),cent·p,93,257765,DB01064,Isoprenaline
,18162599,affinity (K(A)),The pharmacokinetic-pharmacodynamic relationship of isoprenaline was first characterized with the operational model of agonism using the literature value for the affinity (K(A)) of isoprenaline (3.2 x 10(-8) M; left atria WKY rats).,Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),M,3.2 x 10(-8),257983,DB01064,Isoprenaline
,18162599,baseline (E(0)),"Resulting estimates for baseline (E(0)), maximal effect (E(max)), and efficacy (tau) were 374 (1.9%), 130 (5.9%), and 247 (33%) beats per minute, respectively.",Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),,374,257984,DB01064,Isoprenaline
,18162599,maximal effect (E(max)),"Resulting estimates for baseline (E(0)), maximal effect (E(max)), and efficacy (tau) were 374 (1.9%), 130 (5.9%), and 247 (33%) beats per minute, respectively.",Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),[beats] / [min],130,257985,DB01064,Isoprenaline
,18162599,efficacy (tau),"Resulting estimates for baseline (E(0)), maximal effect (E(max)), and efficacy (tau) were 374 (1.9%), 130 (5.9%), and 247 (33%) beats per minute, respectively.",Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),[beats] / [min],247,257986,DB01064,Isoprenaline
,18162599,affinity (K(B)),The estimated in vivo affinity (K(B)) of S(-)-atenolol for the beta(1) -receptor was 4.6 x 10(-8) M.,Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),M,4.6 x 10(-8),257987,DB01064,Isoprenaline
,18162599,affinity,The obtained estimate for in vivo affinity of S(-)-atenolol (4.6 x 10(-8) M) is comparable to literature values for the in vitro affinity in functional assays.,Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),M,4.6 x 10(-8),257988,DB01064,Isoprenaline
,7648772,maximal increase,"The maximal increase in heart rate during isoproterenol infusion after entacapone administration (40 +/- 11 beats/min, mean +/- SD) was statistically greater (p = 0.0496) than after placebo administration (27 +/- 7 beats/min).",The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],40,270060,DB01064,Isoprenaline
,7648772,maximal increase,"The maximal increase in heart rate during isoproterenol infusion after entacapone administration (40 +/- 11 beats/min, mean +/- SD) was statistically greater (p = 0.0496) than after placebo administration (27 +/- 7 beats/min).",The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],27,270061,DB01064,Isoprenaline
,7648772,heart rate,The increase in heart rate during epinephrine infusion was 25 +/- 13 beats/min after entacapone administration and 14 +/- 9 beats/min after placebo administration (p = 0.127).,The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],25,270062,DB01064,Isoprenaline
,7648772,heart rate,The increase in heart rate during epinephrine infusion was 25 +/- 13 beats/min after entacapone administration and 14 +/- 9 beats/min after placebo administration (p = 0.127).,The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],14,270063,DB01064,Isoprenaline
